A 72-year-old man with castration-resistant prostate cancer (PSA progression despite 18 months of GnRH agonist therapy) and bone metastases presents for treatment escalation. Testosterone is <20 ng/dL. What is the preferred next-line hormonal agent?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.